Missing content? – Request curation!
Request curation for specific Genes, variants, or PubMed publications.
Have questions, comments or suggestions? - Let us know!
Email us at : firstname.lastname@example.org
|Therapy Name||Decitabine + Sapacitabine|
|Drug Name||Trade Name||Synonyms||Drug Classes||Drug Description|
|Decitabine||Dacogen||5-aza-2-deoxycytidine||DNMT inhibitor (Pan) 5||Dacogen (decitabine) is cytidine analog that incorporates into DNA and forms covalent bonds with DNA methyltransferases (DNMTs), resulting in decreased DNMT activity and hypomethylation, and potentially leading to reduced tumor growth (PMID: 28159832, PMID: 25130173). Dacogen (decitabine) is FDA approved for use in patients with myelodysplastic syndromes (FDA.gov).|
|Sapacitabine||CS-682|CYC682||Sapacitabine (CS-682) is a nucleoside analog, which interferes with DNA synthesis to induce cell cycle arrest (PMID: 30222471).|
|Molecular Profile||Indication/Tumor Type||Response Type||Therapy Name||Approval Status||Evidence Type||Efficacy Evidence||References|
|Clinical Trial||Phase||Therapies||Title||Recruitment Status|
|NCT01211457||Phase Ib/II||Sapacitabine + Venetoclax Decitabine + Sapacitabine||Study of Sapacitabine in Acute Myeloid Leukemia (AML) or Myelodysplastic Syndromes||Recruiting|
|NCT01303796||Phase III||Decitabine + Sapacitabine Decitabine||A Study of Oral Sapacitabine in Elderly Patients With Newly Diagnosed Acute Myeloid Leukemia (SEAMLESS)||Completed|